Inogen Past Earnings Performance

Past criteria checks 0/6

Inogen's earnings have been declining at an average annual rate of -62.8%, while the Medical Equipment industry saw earnings declining at 1.1% annually. Revenues have been declining at an average rate of 0.7% per year.

Key information

-62.8%

Earnings growth rate

-62.7%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate-0.7%
Return on equity-28.4%
Net Margin-15.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Inogen makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:6IO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24332-5317422
30 Jun 24327-9217023
31 Mar 24322-9716822
31 Dec 23316-10217021
30 Sep 23328-13317020
30 Jun 23349-9617820
31 Mar 23369-9018222
31 Dec 22377-8418022
30 Sep 22366-5017921
30 Jun 22353-2817020
31 Mar 22351-2016718
31 Dec 21358-616217
30 Sep 213561115516
30 Jun 21337-214715
31 Mar 21307-513614
31 Dec 20308-613614
30 Sep 20313-213514
30 Jun 20331613613
31 Mar 203601414111
31 Dec 19362211429
30 Sep 19370321448
30 Jun 19373421487
31 Mar 19369461447
31 Dec 18358521347
30 Sep 18335411207
30 Jun 18309321076
31 Mar 1827626965
31 Dec 1724921885
30 Sep 1723727815
30 Jun 1722225765
31 Mar 1721224725
31 Dec 1620321695
30 Sep 1619219675
30 Jun 1617917645
31 Mar 1616813604
31 Dec 1515912574
30 Sep 151489534
30 Jun 151369493
31 Mar 151237453
31 Dec 141135423
30 Sep 141036393
30 Jun 14943373
31 Mar 14831353
31 Dec 13750322

Quality Earnings: 6IO is currently unprofitable.

Growing Profit Margin: 6IO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 6IO is unprofitable, and losses have increased over the past 5 years at a rate of 62.8% per year.

Accelerating Growth: Unable to compare 6IO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6IO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).


Return on Equity

High ROE: 6IO has a negative Return on Equity (-28.42%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 06:24
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Inogen, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert MarcusJ.P. Morgan
Matthew MishanKeyBanc Capital Markets Inc.
Jeffrey CohenLadenburg Thalmann & Company